Wells Fargo Upgrades Relay Therapeutics to Overweight, Raises Price Target to $13
Benzinga Newsdesk 11 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Wells Fargo analyst Eva Fortea Verdejo upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and raises the price target from $6 to $13.
Wells Fargo analyst Eva Fortea Verdejo upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and raises the price target from $6 to $13.